Abstract
In a Phase I study, melphalan 140 mg/m2 was administered to 8 patients with disseminated malignant melanoma. Marrow was removed from the patients immediately before melphalan administration and returned i.v. 8 h later. Studies on marrow culture and melphalan pharmacokinetics predicted that this was a safe time to administer non-cryopreserved marrow. Four patients received lower doses of i.v. melphalan without autologous marrow. In the group receiving autologous marrow the time for recovery of peripheral-blood granulocytes to 800/mm2 or greater was significantly less (P = 0.01) than in those not receiving marrow. In 7 patients the tumour showed evidence of response to the drug and there was 1 complete remission. This treatment deserves investigation in patients with tumours more sensitive to drugs than melanoma.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- ARIEL I. M., PACK G. T. Treatment of disseminated melanoma with phenylalanine mustard (melphelan) and autogenous bone marrow transplants. Surgery. 1962 May;51:583–591. [PubMed] [Google Scholar]
- CLIFFORD P., CLIFT R. A., DUFF J. K. Nitrogen-mustard therapy combined with autologous marrow infusion. Lancet. 1961 Apr 1;1(7179):687–690. doi: 10.1016/s0140-6736(61)91720-2. [DOI] [PubMed] [Google Scholar]
- Hedley D. W., McElwain T. J., Millar J. L., Gordon M. Y. Acceleration of bone-marrow recovery by pre-treatment with cyclophosphamide in patients receiving high-dose melphalan. Lancet. 1978 Nov 4;2(8097):966–968. doi: 10.1016/s0140-6736(78)92529-1. [DOI] [PubMed] [Google Scholar]
- Humble J. G., Newton K. A., Mellor H., Pegg D. E. Prolonged survival in disseminated seminoma treated to aplasia by wide field X--radiotherapy and phenylalanine mustine with autologous bone marrow cell transfusion cover. Clin Oncol. 1975 Sep;1(3):235–238. [PubMed] [Google Scholar]
- Luce J. K. Chemotherapy of melanoma. Semin Oncol. 1975 Jun;2(2):179–185. [PubMed] [Google Scholar]
- Millar J. L., Phelps T. A., Carter R. L., McElwain T. J. Cyclophosphamide pretreatment reduces the toxic effect of high dose melphalan on intestinal epithelium in sheep. Eur J Cancer. 1978 Nov;14(11):1283–1285. doi: 10.1016/0014-2964(78)90236-0. [DOI] [PubMed] [Google Scholar]
- Pike B. L., Robinson W. A. Human bone marrow colony growth in agar-gel. J Cell Physiol. 1970 Aug;76(1):77–84. doi: 10.1002/jcp.1040760111. [DOI] [PubMed] [Google Scholar]
- Tattersall M. H., Jarman M., Newlands E. S., Holyhead L., Milstead R. A., Weinberg A. Pharmaco-kinetics of melphalan following oral or intravenous administration in patients with malignant disease. Eur J Cancer. 1978 May;14(5):507–513. doi: 10.1016/0014-2964(78)90253-0. [DOI] [PubMed] [Google Scholar]
- Tattersall M. H., Tobias J. S. How strong is the case for intensive cancer chemotherapy? Lancet. 1976 Nov 13;2(7994):1071–1072. doi: 10.1016/s0140-6736(76)90979-x. [DOI] [PubMed] [Google Scholar]
- Tobias J. S., Weiner R. S., Giffiths C. T., Richman C. M., Parker L. M., Yankee R. A. Cryopreserved autologous marrow infusion following high dose cancer chemotherapy. Eur J Cancer. 1977 Mar 29;13(3):269–277. doi: 10.1016/0014-2964(77)90215-8. [DOI] [PubMed] [Google Scholar]
- Weaver P. C., Wright J., Brander W. L., Westbury G. Salvage procedures for locally advanced malignant melanoma of the lower limb (with special reference to the role of isolated limb perfusion and radical lymphadenectomy). Clin Oncol. 1975 Mar;1(1):45–51. [PubMed] [Google Scholar]
- Ziegler J. L., Deisseroth A. B., Applebaum F. R., Graw R. G., Jr Burkitt's lymphoma--a model for intensive chemotherapy. Semin Oncol. 1977 Sep;4(3):317–323. [PubMed] [Google Scholar]